CERO THERAPEUTICS HOLDINGS, INC. (CERO) IPO — S-1 Filing, Stock & Insider Activity

CERO THERAPEUTICS HOLDINGS, INC. IPO — Status & S-1 Filing

Ticker: CERO
Status: Registered — S-1 filed with the SEC
S-1 filed: 2025-12-05
Exchange: NASDAQ
Expected price range: $112.20–$116.40
Shares offered: 729,596,950
SEC CIK: 0001870404 · View the S-1 on SEC EDGAR →

Track every registration update on the InsiderAlpha IPO tracker.

Updated Jul 16, 2026 · Last SEC filing 2026-04-21

CERO THERAPEUTICS HOLDINGS, INC. (CERO) has filed 1 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-04-21. 3 Form 8-K material event filings were reported by CERO in the last 90 days. InsiderAlpha tracks every CERO SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About CERO THERAPEUTICS HOLDINGS, INC. (CERO)

SEC CIK	0001870404

90-Day SEC Filing Activity

Form 4 filings (90d)	1
Form 8-K filings (90d)	3
Latest Form 4 filing	2026-04-21

Recent CERO Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2025-03-31	ATWOOD BRIAN G	Director	M — Option exercise	294.5K	$0.00	$29	SEC
2024-12-13	YK Bioventures Opportunities GP I, LLC	Insider	S — Open-market sale	3.00M	$0.06	$180K	SEC
2024-12-12	YK Bioventures Opportunities GP I, LLC	Insider	S — Open-market sale	1.61M	$0.07	$113K	SEC
2024-12-11	YK Bioventures Opportunities GP I, LLC	Insider	S — Open-market sale	1.34M	$0.08	$108K	SEC
2024-12-10	YK Bioventures Opportunities GP I, LLC	Insider	S — Open-market sale	1.57M	$0.09	$141K	SEC
2024-12-09	YK Bioventures Opportunities GP I, LLC	Insider	S — Open-market sale	850.5K	$0.11	$94K	SEC
2024-12-06	YK Bioventures Opportunities GP I, LLC	Insider	S — Open-market sale	1.24M	$0.12	$148K	SEC
2024-10-10	YK Bioventures Opportunities GP I, LLC	Insider	S — Open-market sale	3.25M	$0.10	$325K	SEC
2024-09-25	LAPORTE KATHLEEN	Director	M — Option exercise	966.0K	—	—	SEC
2024-09-25	ATWOOD BRIAN G	Director	M — Option exercise	19.36M	—	—	SEC
2024-09-25	SLOAN STUART M	10% Owner	S — Open-market sale	532.5K	$0.10	$56K	SEC
2024-09-25	Ehrlich Christopher B	Interim Chairman and CEO	M — Option exercise	5.31M	—	—	SEC

All transactions sourced from SEC EDGAR Form 4 filings for CERO THERAPEUTICS HOLDINGS, INC. (CERO). Updated in real time as new filings are submitted to the SEC.

Most-Active CERO Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
Francois Eric	1	—

Recent CERO Form 8-K Material Events

2026-06-26 — Item 1.01, 2.03, 3.02, 9.01 [SEC]
2026-05-29 — Item 1.01, 2.03, 3.02, 9.01 [SEC]
2026-05-01 — Item 1.01, 2.03, 3.02, 9.01 [SEC]
2026-04-14 — Item 1.01, 2.03, 3.02, 9.01 · Financing · negative [SEC]
CERO Therapeutics issued a convertible promissory note for $350,000 (with $437,500 face value) to Keystone Capital Partners with a maximum borrowing capacity of $1,000,000. The note bears 10% annual interest, matures April 2027, and is convertible into common stock at a price equ
2026-03-10 — Item 1.01, 2.03, 3.02, 9.01 · Financing · negative [SEC]
CERO Therapeutics issued a convertible promissory note for $750,000 (with $937,500 face value) to Keystone Capital Partners, bearing 10% annual interest and maturing August 6, 2027. The note is convertible into common stock at the lesser of $0.05 or 80% of the 20-day average low

Recent Insider Filings

2026-04-21 — Francois Eric (Director)
2026-01-09 — Rolfe Lindsey (Director)
2026-01-09 — LAPORTE KATHLEEN (Director)
2026-01-09 — Pierce Kristen (Chief Development Officer)
2026-01-09 — Patel Shami (Director)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in CERO insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

CERO Insider Trading — FAQ

What is the latest insider trade for CERO?: CERO THERAPEUTICS HOLDINGS, INC. (CERO) had 1 insider filings in the last 90 days, with the most recent on 2026-04-21. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying CERO stock?: 0 insider purchases of CERO were filed in the last 90 days.
How many insiders are selling CERO stock?: 0 insider sales of CERO were filed in the last 90 days.
Where can I see CERO SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every CERO SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Learn More

Open the live CERO dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.